Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

JAZZ | NASDAQ
Chart Builder DCF Calculator
$215.07
-$0.91 (-0.42%)
Nov 2, 2026, 3:58 PM ET · Market open
Fiscal Year
Period Ending
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Net Income
-356.15M 560.12M 414.83M -224.06M -329.67M 238.62M
Depreciation & Amortization
696.3M 660.07M 638.7M 629.47M 552.48M 278.25M
Stock-Based Compensation
291.13M 248.05M 226.84M 222M 189.01M 121M
Other Working Capital
171.37M 10.01M -148.74M 160.91M 36.62M 2.68M
Other Non-Cash Items
1.15B 212.72M 276.29M 926.92M 345.44M 484.16M
Deferred Income Tax
-444.97M -208.33M -260.22M -292.25M 69.2M -136.94M
Change in Working Capital
18.9M -76.72M -204.44M 9.91M -47.95M -85.44M
Operating Cash Flow
1.36B 1.4B 1.09B 1.27B 778.51M 899.65M
Capital Expenditures
-209.75M -48.07M -23.96M -498.19M -45.53M -379.25M
Cash Acquisitions
-858.05M n/a n/a 53M -6.23B -364.25M
Purchase of Investments
-1.83B -1.31B -390.1M -61.04M -26.82M -2.4B
Sales Maturities Of Investments
1.36B 845M 270M 60M 1.1B 1.76B
Other Investing Acitivies
-122.83M -10M -19M n/a -17.89M 378.51M
Investing Cash Flow
-1.51B -508.2M -163.06M -446.23M -5.21B -1.01B
Debt Repayment
-781M 374.77M -31M -582.01M 3.87B 591.81M
Common Stock Repurchased
-125.02M -311.43M -269.76M -54K n/a -146.54M
Dividend Paid
n/a n/a n/a n/a n/a n/a
Other Financial Acitivies
-75.22M -63.47M -50.95M -45.44M -35.6M 99.68M
Financial Cash Flow
-873.38M 20.52M -305.25M -529.49M 3.97B 528.07M
Net Cash Flow
-1.02B 906.55M 624.83M 290.03M -466.32M 420.43M
Free Cash Flow
1.15B 1.35B 1.07B 773.78M 732.98M 520.39M
Adj. Free Cash Flow
854.89M 1.1B 841.2M 551.79M 543.97M 399.4M
Maintenance CapEx
-193.71M -27.63M -7.27M -440.88M n/a -359.95M
Growth CapEx
-16.04M -20.44M -16.69M -57.32M -45.53M -19.3M
Owner Earnings
1.16B 1.37B 1.08B 831.1M 778.51M 539.7M

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.